Drug intelligence / Profile preview

TQB3474

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

TQB3474 is a small molecule inhibitor of heat shock protein 90 (Hsp90), developed for its potential antineoplastic (anti-cancer) activity. By specifically blocking the function of Hsp90, a molecular chaperone involved in stabilizing and activating many proteins required for tumor growth, TQB3474 disrupts multiple signaling pathways essential for cancer cell survival and proliferation. The drug is being investigated primarily for the treatment of advanced solid tumors[1][2][3].

Other names: Hsp90 inhibitor TQB3474Hsp-90 inhibitor TQB3474Hsp 90 inhibitor TQB3474

Targets

HSP90AA1 (Heat shock protein HSP90-alpha)

Beyond the preview

Go deeper on TQB3474.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3474.

Explore the full profile